 |
|
|
|
Trizivir |
|
Detailed Prescribing Information |
|
October 2005 |
|
Trizivir A combination of zidovudine + lamivudine + abacavir |
|
| Forms Available | 300 mg zidovudine / 150 mg lamivudine in tablets / 300 mg abacavir in tablets |
| Dosing | 1 tablet twice a day |
| Renal dosing: not recommended | |
| Hepatic dosing: not recommended | |
| Food dependence | This medication is best taken on an empty stomach. |
| Adverse Effects |
Same as
zidovudine plus
lamivudine
plus
abacavir Primarily bone marrow suppression (leukopenia, granulocytopenia, megaloblastic anemia), nausea, headache Rarely mitochondrial toxicity such as myopathy, cardiomyopathy (case reports only), steatosis, or lactic acidosis 5% incidence of abacavir hypersensitivity |
| Interactions | Same as zidovudine plus lamivudine plus abacavir |
| Suggested lab follow-up |
Monthly CBC and comprehensve metabolic profile
monthly for 3 months, then every 3 months if
stable Check serum lactic acid for symptoms of lactic acidosis (weakness, nausea, anion gap acidosis, etc.) |
| Warning |
5% incidence of abacavir hypersensitivity (see
abacavir)
Rare lactic acidosis and hepatic
steatosis. |
| Contraindication | Previous abacavir hypersensitivity |
|
Suggested administration protocol |
Click HERE to review abacavir administration protocol |
|
Suggested Usage |
Do not use in combination with
lamivudine,
emtricitabine,
Truvada,
Epzicom,
Atripla or Combivir
due to identical mechanism of action or duplication of
lamivudine dosing
or action. Do not use Trizivir with stavudine due to antagonism with the zidovudine component. Do not discontinue abruptly in patients with chronic hepatitis B without consideration of continuation of lamivudine or some other agent active against hepatitis B. |
|
Complete prescribing information |
Trizivir Prescribing Info |
| Links to Antiretroviral Sections (click on anything) |
| Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI) |
| AZT | ddC | ddI | d4T | 3TC | ABC | FTC | TDF | Combivir | Trizivir | Epzicom | Truvada | Atripla |
| Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI) |
| efavirenz | nevirapine | delavirdine |
| Protease Inhibitors (PI) | Boosted Protease Inhibitors |
| saquinavir | indinavir | ritonavir | nelfinavir | amprenavir | lopinavir + ritonavir | atazanavir | fosamprenavir | tipranavir | darunavir |
| Fusion Inhibitors |
| enfuvirtide |
7.14.2006
1. Renal dosing information from: Ian R.
McNicholl & Rudolph A. Rodriguez, MD, Dosing of Antiretroviral Drugs in Renal
Insufficiency and Hemodialysis, May 2004
http://hivinsite.ucsf.edu/InSite?page=md-rr-18
